Melinta Therapeutics Inc.’s next-generation fluroquinolone delafloxacin now has another five years’ of marketing exclusivity, as one of the first drugs to receive a qualified infectious disease product designation under the Generating Antibiotic Incentives Now provisions recently passed by Congress.
Patents covering composition of matter of the Phase III-ready delafloxacin expire in 2016, including additional patent term adjustments or patent term extensions, the company reported in an SEC filing in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?